Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Trachoma as an NTD
- Consequence of trachoma
- Bacterium: Chlamydia trachomatis
- Transmission of trachoma
- Transmission of trachoma (video)
- Pathogenesis (immunopathogenic)
- Anatomy of the eye
- Clinical signs of trachoma
- Normal tarsal conjunctiva
- Trachomatous inflammation: Follicular
- Trachomatous inflammation: Intense
- Trachomatous scarring
- Trachomatous scarring can be subtle
- Trachomatous trichiasis
- Trachomatous trichiasis can be subtle (1)
- Trachomatous trichiasis can be subtle (2)
- Corneal opacity
- Clinical signs are not mutually exclusive (1)
- Clinical signs are not mutually exclusive (2)
- Clinical signs are not mutually exclusive (3)
- Differential diagnoses: Vernal conjunctivitis
- Differential diagnoses: Conjunctival concretions
- Prevalence of signs by age group
- Women are more likely to present TT
- Mapping Trachoma
- The Global Trachoma Mapping Project
- TF1-9 distribution for districts in GTMP
- Global distribution of trachoma
- Summary
Topics Covered
- Introducing trachoma as an NTD
- Individual and social consequences of trachoma
- Transmission of trachoma
- Clinical signs of trachoma
- Global prevalence of trachoma
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Emerson, P. (2020, January 30). Overview of trachoma Part 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 23, 2024, from https://doi.org/10.69645/EAXA1387.Export Citation (RIS)
Publication History
Financial Disclosures
- None
Overview of trachoma Part 1
Published on January 30, 2020
33 min
HSTalks is pleased to grant unrestricted complimentary access to all lectures in the series Neglected Tropical Diseases. Persons not at a subscribing institution should sign up for a personal account.
Other Talks in the Series: Neglected Tropical Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Dr. Paul Emerson.
I'm the Director of
the International Trachoma Initiative here at the Task Force for Global Health,
Heart of Emory University in Atlanta.
In these talks on trachoma,
we're going to have two sections.
Section 1 is the epidemiology of
trachoma and how we have mapped trachoma around the world,
and in the second part of the talk,
we're going to talk about the global program to eliminate
trachoma and progress and challenges to elimination.
0:40
As you know by now trachoma is one of the neglected tropical diseases.
This one affects the eyes, it is miserable,
it's debilitating, and it's stigmatizing,
causes disability, low vision, and blindness.
It disproportionately affects the poorest people
in the world and not only does it affect them,
it causes them to stay in poverty as it cycles within families.
It affects eyes as we mentioned,
but the eyes are in people,
the people live in families,
the families live in communities.
Ultimately, it's a public health problem that affect nation-states.
So because it is a national program in
the affected countries that affects a large number of people,
it is the desire of the country to eliminate blinding trachoma,
and it's not going to be something that partners or donors can do.
It's very important in all of these programs to
remember that in order for them to be successful,
the communities and the people in
the communities have to want to be a part of the program.
They are not passive recipients of our largesse,
they are active consumers and
active participants in a program that they want to see achieve.